GDTC
CytoMed Therapeutics Limited Ordinary Shares
NASDAQ: GDTC · HEALTHCARE · BIOTECHNOLOGY
$1.00
+0.71% today
Updated 2026-04-30
Market cap
$11.60M
P/E ratio
—
P/S ratio
13.47x
EPS (TTM)
$-0.27
Dividend yield
—
52W range
$1 – $4
Volume
0.0M
WallStSmart proprietary scores
28
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+8.0
Quality
A2.5
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
2.3
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$5.00
+401.50%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 46.90% QoQ
+ Debt/equity 0.07x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-1.83M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $270335.00 | $290560.00 | $52005.00 | $248269.00 | $860850.00 |
| Net income | $-2.27M | $-3.13M | $-1.88M | $-3.05M | $-1.35M |
| EPS | — | — | — | — | $-0.27 |
| Free cash flow | $-1.46M | $-2.63M | $-2.72M | $-4.40M | $-1.83M |
| Profit margin | -839.94% | -1,077.85% | -3,621.15% | -1,227.07% | — |
Peer comparison
Smart narrative
CytoMed Therapeutics Limited Ordinary Shares trades at $1.00. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 2.34, it sits in the grey zone. TTM revenue stands at $860850.00.
Frequently asked questions
What is CytoMed Therapeutics Limited Ordinary Shares's stock price?
CytoMed Therapeutics Limited Ordinary Shares (GDTC) trades at $1.00.
Is CytoMed Therapeutics Limited Ordinary Shares overvalued?
Smart Value Score 28/100 (Grade F, Strong Sell).
What is the price target of CytoMed Therapeutics Limited Ordinary Shares (GDTC)?
The analyst target price is $5.00, representing +401.5% upside from the current price of $1.00.
What is CytoMed Therapeutics Limited Ordinary Shares's revenue?
TTM revenue is $860850.00.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
2.34 — grey zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio13.47x
ROE-50.30%
Beta-0.21
50D MA$1.03
200D MA$1.58
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—